Antibody-Drug Target

Therapeutic antibodies are a growing class of drugs. About a hundred of them have been validated and hundreds are in development or clinical phases! They have been developed against various disorders including cancer and autoimmune diseases. Their ability to target specifically the proteins and molecules involved in the pathophysiological process made them successful in clinic studies. The further development of antibodies through the study of their targets and their pathways is very promising in drug target discovery! This research goes from the screening and validation drug targets and the synthesis and analysis of the antibody which may be done on a biosimilar antibody.

ProteoGenix offers the largest biosimilar antibodies catalog and their corresponding targets!

These proteins include naked monoclonal antibodies but also antibody drug conjugates and bispecific antibodies.

Naked monoclonal antibodies, upon binding to a pathogen, signal its presence to immune cells as macrophages. This system is the Antibody-Dependent Cell-mediated Cytotoxic (ADCC). They may also induce the production of a complex that will trigger the pathogen cell lysis in Complement-Dependent Cytotoxicity (CDC). They can also block tumor pathways to slow down their spreading. Antibody-Drug Conjugates (ADCs) are complexes composed of drug molecules and the antibody. The latter thus lead the former directly to its target sparing important drug amounts. Bispecific antibodies are molecules that can bind to two different targets.

The Drug-Antibodies all target different proteins that play key roles in pathways that are disrupted by diseases. Among these proteins, many are immune checkpoints. Immune inhibitors as CTLA-4 for example may be blocked to let a tumor cell undergo apoptosis. Some cancer biomarkers are also studied as targets for the treatment of this disease. As cancer involves the uncontrolled cell division, growth factors are one of the aspects of oncology studies. Cytokines such as interleukins are also often targeted as signal proteins are responsible for many diseases development. Although many therapeutic antibodies are developed to treat cancer, others are focused on developmental biology, metabolism, virology or auto-immune diseases.